Name:

Verification:

Answer the above question:

(CustomImgCaptcha By Surrey Forum)

Message:

<p>[QUOTE=&quot;anonymous, post: 5814752&quot;]Look, first off, for the people talking Nevro up, just go to an SCS patient forum. spine-health.com seems to be pretty good for SCS stuff. I&#039;ve never seen complaints like you&#039;ll read there. Yeah the IPG is huge - i think it&#039;s twice the size of the competitors. A couple people complained that it was so big that it actually cut through their skin from the inside. And people there also complain about hot batteries - theyre big, and have to be recharged daily. And the intense post-surgical pain (probably because it&#039;s so big). And, no, Nevro is not a mass market device. Their system is aimed at a particular niche - I&#039;ll look it up and see what I can find.</p><p><br /></p><p>So, for NVTR, nobody else&#039;s leads are stretchy. Some significant portion of people don&#039;t convert to permanent from trial, b/c complications or poor efficacy (e.g., poor lead placement). NVTR fixes that problem - first, leads are stretchy, so won&#039;t break/migrate -&gt; less complications during this trial phase. And they have really awesome electrode technology - they basically figured out a way to make an electrode array that was much smaller, but with the same impedance as the competitors&#039; larger arrays (important so it doesn&#039;t use more power). So it&#039;s easier to steer into the epidural space. And also, theyre the only one with 12 electrodes on an array (b/c coil-in-coil lead body), which means the doc doesn&#039;t have to pick which of the 3 dermatomes to cover - this is huge, by the way - you just cover all dermatomes, and then it&#039;s to programming to see which ones to turn off (and they can turn them off, b/c they have triphase electrodes; the other company with independent power sources is only biphase, i believe, which means only positive or negative charges). Between steerability and full dermatome coverage, algovita&#039;s efficacy should be relatively high compared to the competitors. And then, once we&#039;ve converted to permanent, obviously fewer complications (from lead breakage/migration, or roughly 22% of patients) is something that payers, doctors, and patients would all react to positively.</p><p><br /></p><p>One of the big things here is their platform. So, just filed for SNS approvals today. Have a development agreement with Aleva, which does DBS. Aleva&#039;s DBS crushes the current options. The current options have a cylindrical lead tip, and they apply stimulation around the entire cylinder (e.g., the electrode is a single ring). Aleva has a lead tip that&#039;s also cylindrical, but they&#039;ve placed 3 separate electrodes around the ring, instead of having one ring-shaped electrode. And with nvtr&#039;s independent power sources, they can offer directional stimulation, which is pretty darn important when we&#039;re talking about pumping electricity into the brain. </p><p><br /></p><p>Once the 12 electrode lead (full 3 dermatome coverage) is placed, then it&#039;s just a matter of programming, and they have algorithms that assist here - very doctor friendly. the patient key fob is small and discrete, and the thing only needs to be charged twice per week, despite the fact that it&#039;s smaller (volume wise) than the competitors.</p><p><br /></p><p>Regarding HF, they already go up to 2000 hz or w/e. As mentioned, Greatbatch bought CCC. And mgmt has indicated that their IPG has capabilities that they haven&#039;t requested approval for yet, b/c they wanted to approve the simplest device (to get a literature based approval). So, fairly certain that the device does have the ability to go up to 10, where nevro is, but they haven&#039;t activated that feature. MRI compatibility coming out in the first half of this year, I think. Accelerometer might be included in that upgrade, too. And, b/c the platform device is constant across indications, I think they&#039;ll be able to upgrade all of them without actually having to do multiple product upgrade and fda approval processes (not certain here, but fairly sure). So, they&#039;ll be able to upgrade their whole portfolio at once - talk about improving time to market.</p><p><br /></p><p>They actually do have a number of breakthrough technologies, including the stretchy lead body and the tiny electrode array. There&#039;s alot of detail i haven&#039;t gone into b/c space constraints, too. And these are things the industry has been after, and hasn&#039;t been able to get. I know this from reading Medtronic&#039;s patents - they call out what the &quot;long felt needs&quot; of the industry are.&nbsp; But they&#039;re not engineering bells and whistles, which it seems you guys are looking for. It is truly an advanced, differentiated product. It&#039;s just that the differentiation / tech aspects aren&#039;t really glittery. But if you read those patents of theirs, it&#039;s pretty impressive. I think it&#039;s just a question of &quot;Can they sell it?&quot; Too early to tell, but i guess we&#039;ll see.[/QUOTE]</p><p><br /></p>

Your name or email address:

Do you already have an account?

• No, create an account now.
• Yes, my password is:
• Forgot your password?

Stay logged in